Brinzolamide-timolol suspension: Acceptability and side effect profile

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 419-423

  Doherty, M D ^a   Fraser, S G ^a   Phelan, P S ^a  

^a SUNDERLAND EYE INFIRMARY   (United Kingdom)

Author keywords

Glaucoma; Intraocular pressure; Quality of life; Side effects

Indexed keywords

BRINZOLAMIDE PLUS TIMOLOL;

AGED; ARTICLE; BLURRED VISION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG EFFECT; DRUG RESPONSE; DRUG TOLERABILITY; EYE DISCOMFORT; EYE IRRITATION; FEMALE; GLAUCOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; QUALITY OF LIFE; QUANTITATIVE STUDY; QUESTIONNAIRE; SUSPENSION; TREATMENT DURATION;

EID: 79956344415     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S18251     Document Type: Article

References (14)

1. Beckers HJ, Schouten JS, Webers CA. Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2009;3:593-599.
2. Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2009;18:293-300.
3. Kaback M, Scoper SV, Arzeno G, et al. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology. 2008;115: 1728-1734.
4. Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: Results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol. 2000; 44 Suppl 2: S141-S145.
5. Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: A systematic classification. J Glaucoma. 2003;12:393-398.
6. Kass MA, Gordon M, Morley RE Jr, Meltzer DW, Goldberg JJ. Compliance with topical timolol treatment. Am J Ophthalmol. 1997; 103:188-193.
7. Silver LH. Brinzolamide Primary Therapy Study Group. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 1998;126:400-408.
8. Michaud JE, Friren B; the International Brinzolamide Adjunctive Study Group. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:235-243.
9. Day DG, Sharpe ED, Atkinson MJ, et al. The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients. Eye. 2006;20:583-590.
10. Stewart WC, Day DG, Stewart JA, et al. Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects. Eye. 2004;18:905-910.
11. Mundorf TK, Rauchman SH, Williams RD, Notivol R; Brinzolamide/Timolol Preference Study Group. A patient preference comparison of Azarga (brinzolamide/timolol f ixed combination) vs Cosopt (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2008;2:623-628.
12. Jampel HD, Schwartz GF, Robin AL, et al. Patient preferences for eye drop characteristics: A willingness-to-pay analysis. Arch Ophthalmol. 2003;121:540-546.
13. Vold SD, Evans RM, Stewart RH, Walters T, Mallick S. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2008;24:601-605.
14. Strahlman E, Tipping R, Vogel R; International Dorzolamide Study Group. A double masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch Ophthalmol. 1995; 113:1009-1016.